Genfit plans Phase 2 trial of nangibotide in acute-on-chronic liver failure
- Genfit will present clinical data supporting nangibotide’s advancement into Phase 2 for acute-on-chronic liver failure on November 8, 2026.
- Previous studies in other indications provided safety data and promising efficacy signals across multiple organ systems.
- November 6 presentations will show additional evidence of nitazoxanide’s anti-inflammatory activity from clinical blood samples, supporting development for acute-on-chronic liver failure.
- A separate November 6 panel will discuss NIS non-invasive diagnostics for identifying at-risk MASH patients and monitoring treatment response.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020130PRIMZONEFULLFEED1001280946) on November 02, 2026, and is solely responsible for the information contained therein.